Literature DB >> 24503131

Role of the intestinal microbiota in resistance to colonization by Clostridium difficile.

Robert A Britton1, Vincent B Young2.   

Abstract

Antibiotic-associated infection with the bacterial pathogen Clostridium difficile is a major cause of morbidity and increased health care costs. C difficile infection follows disruption of the indigenous gut microbiota by antibiotics. Antibiotics create an environment within the intestine that promotes C difficile spore germination, vegetative growth, and toxin production, leading to epithelial damage and colitis. Studies of patients with C difficile infection and animal models have shown that the indigenous microbiota can inhibit expansion and persistence of C difficile. Although the specific mechanisms of these processes are not known, they are likely to interfere with key aspects of the pathogen's physiology, including spore germination and competitive growth. Increasing our understanding of how the intestinal microbiota manage C difficile could lead to better means of controlling this important nosocomial pathogen.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibiotics; C difficile; Colonization Resistance; Microbial Ecology; Microbiome

Mesh:

Substances:

Year:  2014        PMID: 24503131      PMCID: PMC3995857          DOI: 10.1053/j.gastro.2014.01.059

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  65 in total

Review 1.  From structure to function: the ecology of host-associated microbial communities.

Authors:  Courtney J Robinson; Brendan J M Bohannan; Vincent B Young
Journal:  Microbiol Mol Biol Rev       Date:  2010-09       Impact factor: 11.056

2.  Analysis of proline reduction in the nosocomial pathogen Clostridium difficile.

Authors:  Sarah Jackson; Mary Calos; Andrew Myers; William T Self
Journal:  J Bacteriol       Date:  2006-10-13       Impact factor: 3.490

3.  Susceptibility of hamsters to human pathogenic Clostridium difficile strain B1 following clindamycin, ampicillin or ceftriaxone administration.

Authors:  Michelle Merrigan; Susan Sambol; Stuart Johnson; Dale N Gerding
Journal:  Anaerobe       Date:  2003-04       Impact factor: 3.331

4.  Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains.

Authors:  Casey M Theriot; Charles C Koumpouras; Paul E Carlson; Ingrid I Bergin; David M Aronoff; Vincent B Young
Journal:  Gut Microbes       Date:  2011-11-01

5.  Enterotypes of the human gut microbiome.

Authors:  Manimozhiyan Arumugam; Jeroen Raes; Eric Pelletier; Denis Le Paslier; Takuji Yamada; Daniel R Mende; Gabriel R Fernandes; Julien Tap; Thomas Bruls; Jean-Michel Batto; Marcelo Bertalan; Natalia Borruel; Francesc Casellas; Leyden Fernandez; Laurent Gautier; Torben Hansen; Masahira Hattori; Tetsuya Hayashi; Michiel Kleerebezem; Ken Kurokawa; Marion Leclerc; Florence Levenez; Chaysavanh Manichanh; H Bjørn Nielsen; Trine Nielsen; Nicolas Pons; Julie Poulain; Junjie Qin; Thomas Sicheritz-Ponten; Sebastian Tims; David Torrents; Edgardo Ugarte; Erwin G Zoetendal; Jun Wang; Francisco Guarner; Oluf Pedersen; Willem M de Vos; Søren Brunak; Joel Doré; María Antolín; François Artiguenave; Hervé M Blottiere; Mathieu Almeida; Christian Brechot; Carlos Cara; Christian Chervaux; Antonella Cultrone; Christine Delorme; Gérard Denariaz; Rozenn Dervyn; Konrad U Foerstner; Carsten Friss; Maarten van de Guchte; Eric Guedon; Florence Haimet; Wolfgang Huber; Johan van Hylckama-Vlieg; Alexandre Jamet; Catherine Juste; Ghalia Kaci; Jan Knol; Omar Lakhdari; Severine Layec; Karine Le Roux; Emmanuelle Maguin; Alexandre Mérieux; Raquel Melo Minardi; Christine M'rini; Jean Muller; Raish Oozeer; Julian Parkhill; Pierre Renault; Maria Rescigno; Nicolas Sanchez; Shinichi Sunagawa; Antonio Torrejon; Keith Turner; Gaetana Vandemeulebrouck; Encarna Varela; Yohanan Winogradsky; Georg Zeller; Jean Weissenbach; S Dusko Ehrlich; Peer Bork
Journal:  Nature       Date:  2011-04-20       Impact factor: 49.962

6.  Colonic absorption of unconjugated bile acids: perfusion studies in man.

Authors:  H S Mekhjian; S F Phillips; A F Hofmann
Journal:  Dig Dis Sci       Date:  1979-07       Impact factor: 3.199

7.  Carbohydrate fermentation by Clostridium difficile.

Authors:  S Nakamura; S Nakashio; K Yamakawa; N Tanabe; S Nishida
Journal:  Microbiol Immunol       Date:  1982       Impact factor: 1.955

8.  Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation.

Authors:  Dionysios A Antonopoulos; Susan M Huse; Hilary G Morrison; Thomas M Schmidt; Mitchell L Sogin; Vincent B Young
Journal:  Infect Immun       Date:  2009-03-23       Impact factor: 3.441

9.  A framework for human microbiome research.

Authors: 
Journal:  Nature       Date:  2012-06-13       Impact factor: 49.962

10.  Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut.

Authors:  Elaine O Petrof; Gregory B Gloor; Stephen J Vanner; Scott J Weese; David Carter; Michelle C Daigneault; Eric M Brown; Kathleen Schroeter; Emma Allen-Vercoe
Journal:  Microbiome       Date:  2013-01-09       Impact factor: 14.650

View more
  159 in total

Review 1.  The gut microbiome in health and in disease.

Authors:  Andrew B Shreiner; John Y Kao; Vincent B Young
Journal:  Curr Opin Gastroenterol       Date:  2015-01       Impact factor: 3.287

Review 2.  Gastrointestinal dysbiosis and the use of fecal microbial transplantation in Clostridium difficile infection.

Authors:  L Patrick Schenck; Paul L Beck; Justin A MacDonald
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

Review 3.  Host Microbiota Contributes to Health and Response to Disease.

Authors:  Rajeev Aurora; Thomas Sanford
Journal:  Mo Med       Date:  2015 Jul-Aug

4.  Microbiome as mediator: Do systemic infections start in the gut?

Authors:  Melissa Latorre; Suneeta Krishnareddy; Daniel E Freedberg
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

Review 5.  Considering the Immune System during Fecal Microbiota Transplantation for Clostridioides difficile Infection.

Authors:  Alyse L Frisbee; William A Petri
Journal:  Trends Mol Med       Date:  2020-02-17       Impact factor: 11.951

Review 6.  Immune-based treatment and prevention of Clostridium difficile infection.

Authors:  Song Zhao; Chandrabali Ghose-Paul; Keshan Zhang; Saul Tzipori; Xingmin Sun
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Predominance of Lactobacillus spp. Among Patients Who Do Not Acquire Multidrug-Resistant Organisms.

Authors:  Rafael Araos; Albert K Tai; Graham M Snyder; Martin J Blaser; Erika M C D'Agata
Journal:  Clin Infect Dis       Date:  2016-06-28       Impact factor: 9.079

8.  Proton Pump Inhibitors Do Not Increase Risk for Clostridium difficile Infection in the Intensive Care Unit.

Authors:  David M Faleck; Hojjat Salmasian; E Yoko Furuya; Elaine L Larson; Julian A Abrams; Daniel E Freedberg
Journal:  Am J Gastroenterol       Date:  2016-08-30       Impact factor: 10.864

9.  Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.

Authors:  Zhiyong Yang; Jeremy Ramsey; Therwa Hamza; Yongrong Zhang; Shan Li; Harris G Yfantis; Dong Lee; Lorraine D Hernandez; Wolfgang Seghezzi; Jamie M Furneisen; Nicole M Davis; Alex G Therien; Hanping Feng
Journal:  Infect Immun       Date:  2014-12-08       Impact factor: 3.441

10.  Clostridioides difficile uses amino acids associated with gut microbial dysbiosis in a subset of patients with diarrhea.

Authors:  Eric J Battaglioli; Vanessa L Hale; Jun Chen; Patricio Jeraldo; Coral Ruiz-Mojica; Bradley A Schmidt; Vayu M Rekdal; Lisa M Till; Lutfi Huq; Samuel A Smits; William J Moor; Yava Jones-Hall; Thomas Smyrk; Sahil Khanna; Darrell S Pardi; Madhusudan Grover; Robin Patel; Nicholas Chia; Heidi Nelson; Justin L Sonnenburg; Gianrico Farrugia; Purna C Kashyap
Journal:  Sci Transl Med       Date:  2018-10-24       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.